Fas expression in non-small cell lung cancer: its prognostic effect in completely resected stage III patients

被引：42

作者：

Uramoto, H ^{[1
]}

Osaki, T ^{[1
]}

Inoue, M ^{[1
]}

Taga, S ^{[1
]}

Takenoyama, M ^{[1
]}

Hanagiri, T ^{[1
]}

Yoshino, I ^{[1
]}

Nakanishi, R ^{[1
]}

Ichiyoshi, Y ^{[1
]}

Yasumoto, K ^{[1
]}

机构：

[1] Univ Occupat & Environm Hlth, Sch Med, Dept Surg 2, Yahatanishi Ku, Kitakyushu, Fukuoka 8078555, Japan

来源：

EUROPEAN JOURNAL OF CANCER | 1999年 / 35卷 / 10期

关键词：

Fas protein; non-small cell lung cancer; immunohistochemical analysis; prognostic factor;

D O I：

10.1016/S0959-8049(99)00157-4

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

SThe aim of this study was to examine Pas expression in non-small cell lung cancer (NSCLC) and examine its correlation with clinicopathological features and prognosis. Pas expression was determined by an immunohistochemical analysis using the labelled streptavidin-biotin method from 220 paraffin specimens of completely resected primary stage I-III NSCLC. 80 (36%) of 220 cases-were positive for Fas immunostaining. These 80 Gases included 44 adenocarcinomas (33%) and 30 squamous cell carcinomas (40%). 33 stage I (33%) 13 (43%) stage II and 34 (37%) stage III tumours were Pas positive. No statistically significant differences were observed regarding the Pas status with respect to age, sex, histological type, or stage of disease. There was no significant difference in survival between early stage (stages I-II) disease pateints with positive Fas expression and those with a negative expression (P = 0.719). However, for patients with completely resected stage III tumours, the patients with positive Pas staining were found to survive for a longer period than those with negative staining (P = 0.026). (C) 1999 Elsevier Science Ltd, All rights reserved.

引用

页码：1462 / 1465

页数：4

共 22 条

[1] Melanoma cell expression of Fas(Apo-1/CD95) ligand: Implications for tumor immune escape [J].